Evidence map›Paper›PMID 34012393›Full record

ReviewFrontiers in pharmacology2021

Analysis of Pharmacokinetics in the Cochlea of the Inner Ear.

Seishiro Sawamura, Genki Ogata, Kai Asai, Olga Razvina, Takeru Ota, Qi Zhang, Sasya Madhurantakam, Koei Akiyama, Daisuke Ino, Sho Kanzaki and 7 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Seishiro SawamuraDivision of Glocal Pharmacology, Department of Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Genki OgataDivision of Glocal Pharmacology, Department of Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Kai AsaiDepartment of Chemistry, Keio University, Yokohama, Japan.
Olga RazvinaDepartment of Molecular Physiology, Niigata University School of Medicine, Niigata, Japan.
Takeru OtaDivision of Glocal Pharmacology, Department of Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Qi ZhangDivision of Glocal Pharmacology, Department of Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Sasya MadhurantakamDivision of Glocal Pharmacology, Department of Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Koei AkiyamaDepartment of Molecular Physiology, Niigata University School of Medicine, Niigata, Japan.
Daisuke InoDivision of Glocal Pharmacology, Department of Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Sho KanzakiDepartment of Otolaryngology, School of Medicine, Keio University, Tokyo, Japan.
Takuro SaikiDepartment of Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Yoshifumi MatsumotoDepartment of Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Masato MoriyamaDepartment of Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Yasuo SaijoDepartment of Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Arata HoriiDepartment of Otolaryngology, Head and Neck Surgery Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Yasuaki EinagaDepartment of Chemistry, Keio University, Yokohama, Japan.
Hiroshi HibinoDivision of Glocal Pharmacology, Department of Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Niigata University · JPOsaka University · JPKeio University · JPJapan Agency for Medical Research and Development · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hearing loss affects >5% of the global population and therefore, has a great social and clinical impact. Sensorineural hearing loss, which can be caused by different factors, such as acoustic trauma, aging, and administration of certain classes of drugs, stems primarily from a dysfunction of the cochlea in the inner ear. Few therapeutic strategies against sensorineural hearing loss are available. To develop effective treatments for this disease, it is crucial to precisely determine the behavior of ototoxic and therapeutic agents in the microenvironment of the cochlea in live animals. Since the 1980s, a number of studies have addressed this issue by different methodologies. However, there is much less information on pharmacokinetics in the cochlea than that in other organs; the delay in ontological pharmacology is likely due to technical difficulties with accessing the cochlea, a tiny organ that is encased with a bony wall and has a fine and complicated internal structure. In this review, we not only summarize the observations and insights obtained in classic and recent studies on pharmacokinetics in the cochlea but also describe relevant analytical techniques, with their strengths, limitations, and prospects.

Indexed as

cochleaototoxic drugpharmacokineticsreal-time measurementsensorineural hearing losstherapeutic reagent

Identifiers

PMID34012393
PMCPMC8128070
OpenAlexW3159476791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.